Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

Next Previous
X
Search
Trial Profile

A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Dec 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Guselkumab (Primary)
  • Indications Psoriatic arthritis
  • Focus Therapeutic Use
  • Acronyms STAR
  • Sponsors Janssen Research & Development; Janssen-Cilag

    • Most Recent Events

    • 14 Aug 2024 Planned End Date changed from 4 Jun 2026 to 10 Nov 2026.
    • 18 Jun 2024 Planned End Date changed from 13 Feb 2026 to 4 Jun 2026.
    • 15 Jun 2024 Results(n=487) of exploratory analysis of available screening MRI data from STAR compared clinical characteristics between pts meeting vs not meeting STAR MRI eligibility criteria , presented at the 25th Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top